This review presents and discusses results from clinical studies evaluating PD-1/PD-L1 and CTLA-4 inhibitor combinations, highlighting current achievements, clinical limitations, and future directions in cancer immunotherapy. This evidence concerns the gene CTLA4 and cancer.